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Abstract Lymphomas with primary or secondary in-
volvement of central nervous system (CNS) have poor
prognosis despite specific treatment protocols which in-
clude whole brain radiotherapy and high-dose systemic
and/or intrathecal chemotherapy. Toxicity of intrathecal
liposomal cytarabine-based regimens collected between
November 2006 and January 2012 was assessed retro-
spectively. Data from 120 adult lymphoma patients with, or
at high risk of CNS involvement who received intrathecal
liposomal cytarabine-based regimens at six Polish Lym-
phoma Research Group centres between November 2006
and January 2012 were assessed retrospectively. Patients
were divided into three cohorts: A (high risk of CNS dis-
ease, n = 88), B (cerebrospinal fluid pleocytosis without
neurological symptoms or pathological imaging findings,
n = 7), and C (CNS disease/neurological involvement;
n = 25). In all examined groups, toxicity of treatment was
found to be acceptable (including the prophylactic setting).
None of the patients in cohorts A or B who took intrathecal
liposomal cytarabine 50 mg, repeated every 2–4 weeks
(mean 3.8 doses) had experienced a CNS relapse at a
median follow-up time of 3 years. Patients in cohort C had
a 76 % overall neurological response rate (including a
40 % complete response rate) and median overall survival
of 4.8 years. Regimens incorporating liposomal cytarabine
seem to be safe and effective treatments for lymphomas
with CNS involvement.
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Introduction
Central nervous system (CNS) involvement is a serious,
life-shortening complication of non-Hodgkin’s lymphoma
(NHL), with a prevalence ranging from\3 % in indolent to
30 % in aggressive forms of the disease [1–4]. Current
treatment options for CNS lymphoma (high-dose CNS-
penetrating chemotherapy and/or whole brain radiation
therapy; WBRT) are rarely curative [3, 4]. Moreover,
toxicity of treatment is commonly at unacceptable level.
Primary CNS lymphoma (PCNSL) has a particularly poor
prognosis, with approximately 90 % of relapsing/refractory
cases [5]. Aggressive NHL subtypes like DLBCL with
secondary CNS involvement have a median survival time
of 2–6 months;\25 % of the patients are alive 1 year after
diagnosis [2, 3, 5].
CNS-directed therapy is a widely accepted standard in the
first line therapy of lymphoblastic and Burkitt’s lymphomas,
where the risk of CNS relapses exceeds 20 % [6]. Most cases,
however, occur in patients with diffuse large B cell lym-
phoma (DLBCL), peripheral T cell lymphoma and other
‘‘intermediate grade lymphomas’’ which have a cumulative
incidence of secondary CNS involvement at a rate of 1–26 %
at 5 years, depending on the risk group [1, 7–10].
CNS prophylaxis in high-risk asymptomatic cases
might, therefore, be recommended as a standard practice
after a risk assessment including the analysis of effective-
ness and potential toxicity of prophylactic agents. R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine,
and prednisone), the most commonly used protocol in
DLBCL has poor CNS penetration and has no effect on the
CNS relapse rate [9, 11–15].
The marginally decreased incidence of CNS relapses in
the R-CHOP era might be related to decreased number of
systemic relapses [12, 16]. Although intrathecally admin-
istered anti-metabolites methotrexate (MTX) and/or cy-
tarabine reduce relapse rates, their efficacy is compromised
by pharmacokinetic issues. The relatively short half-lives
of MTX and cytarabine (3.4 and 4.5 h, respectively) may
result in inadequate biodistribution—homogenous, cyto-
toxic concentrations in the entire leptomeningeal com-
partment are difficult to achieve [17]. To achieve constant
therapeutic concentrations of MTX and/or cytarabine, 2–3
lumbar punctures would have been necessary every week,
which is uncomfortable and inconvenient for the patient.
Less frequent intrathecal cytostatic administration, widely
used in DLBCL patients is probably suboptimal, even in
prophylaxis, as reflected by some study results [11, 12, 18].
Liposomal cytarabine (DepoCyte) is a slow-release
formulation that maintains cytotoxic concentrations in the
cerebrospinal fluid (CSF) for at least 14 days in adults after
a single intrathecal injection, achieving extensive distri-
bution throughout the neuraxis. This formulation comprises
aqueous chambers of the active drug (cytarabine) encap-
sulated within spherical, biodegradable lipid bi-layers
which form 3- to 30-lm-diameter particles (DepoFoam),
suspended in a 0.9 % sodium chloride solution. The CNS
half-life of an intrathecal liposomal cytarabine in a
12.5–75 mg dose is 29- to 77-fold greater than a 30 mg
dose of intrathecal free cytarabine (100–263 vs. 3.4 h) [19,
20]. Furthermore, cytotoxic concentrations (C0.1 mg/ml)
are maintained in the CSF for [14 days in most adults
following a single liposomal cytarabine dose compared to
\24 h for free cytarabine. Intrathecal liposomal cytarabine
also demonstrated a significantly higher response rate and
greater quality of life improvement than intrathecal cy-
tarabine or MTX in the treatment of lymphomatous
meningitis [21–23]. The treatment toxicity issue is still
under investigation; this is particularly important for the
prophylaxis setting where at least some of the patients may
not have CNS involvement.
This retrospective analysis evaluated the tolerability of
liposomal cytarabine-based regimens in the treatment or
prevention of CNS involvement in patients with aggressive
NHL (mainly high-risk DLBCL). It addresses the adverse
events (AEs) of liposomal cytarabine including serious
ones such as myelopathy. Other aspects will include an
efficacy analysis of CNS lymphoma treatment and whether
the benefits of prophylaxis outweigh the risks.
Materials and methods
Toxicity and efficacy of intrathecal liposomal cytarabine
(Depocyte)-based regimens, administered in 120 adult
lymphoma patients with, or at high risk of CNS involve-
ment who received liposomal cytarabine regimens at six
Polish Lymphoma Research Group (PLRG) centers be-
tween November 2006 and January 2012 were analysed
retrospectively.
Each patient underwent clinical assessments, neuro-
logical examinations, complete blood cell and biochemical
profiling, a bone marrow biopsy, whole-body computed
tomography (CT), and/or nuclear magnetic resonance
(NMR) to confirm systemic disease status and/or the
presence of CNS involvement. Complete blood cell count,
biochemical profiling, CSF analysis (cell count and cy-
tology), and a neurological examination were conducted
prior to each liposomal cytarabine administration. The
cytological method is less accurate than flow cytometry, so
minor CSF involvement could have been missed. AEs,
classified according to version 4.0 of the Common Ter-
minology Criteria for Adverse Events of the National
Cancer Institute (NCI-CTCAE v 4.0), were assessed and
recorded at each hospital visit. Event-free survival (EFS)
was assessed clinically and by CT/NMR imaging and
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defined as the time from the first intrathecal injection of
liposomal cytarabine until death, disease progression or
relapse. Overall survival (OS) was measured from the time
of the first dose of liposomal cytarabine until death or the
last observation. Descriptive statistics were used to sum-
marize patient characteristics. Time-to-event curves and
median time-to-event (EFS, OS) values were generated
using the Kaplan–Meier method.
Depocyte was used for the prophylaxis (cohort A) or
treatment (cohorts B and C) of CNS involvement. Mean
patient age was 47 years (range 18–79), 60 % (n = 72)
were males, and the most common histological subtype
was DLBCL (diffuse large cell lymphoma, n = 80, 67 %).
Overall, 89.2 % (n = 107) of cases were treated at diag-
nosis, while 10.8 % (n = 13) were treated for disease re-
lapse. Patients’ baseline characteristics are summarized in
Table 1. Patients in cohort A (n = 88) were diagnosed
with lymphoblastic (LB) or Burkitt’s (BL) lymphomas
(n = 13, 14.8 %) or high-risk DLBCL or other aggressive
lymphomas (n = 75, 85.2 %). None of them had any
symptoms or signs of CNS involvement, nor increased
pleocytosis in cerebrospinal fluid (CSF) analysis. ‘High-
risk’ DLBCL or other aggressive NHL was defined as:
lymphoma cell infiltration at specific sites (vertebral col-
umn, orbits, sinuses, testes: n = 17, 19.3 %) or existence
of at least 2 out of 3 recognized risk factors: an IPI score of
3–5; elevated serum LDH; involvement at C2 extranodal
sites, (n = 68, 77.3 %). They received prophylaxis with
intrathecal liposomal cytarabine, 50 mg every 2–4 weeks.
Patients in cohort B (n = 7) had measurable systemic
disease and clinically important CSF pleocytosis, defined
as a lymphoma cell count [15/ll (mean 39 cells/ll, range
15–164/ll) without neurological symptoms or radiological
CNS involvement. They received intrathecal liposomal
cytarabine, 50 mg every 2–4 weeks with curative intent,
plus concomitant non-CNS-penetrating systemic
chemotherapy.
Patients in cohort C (n = 25) had CNS involvement
diagnosed on imaging studies (eight in CT, ten in NMR,
seven in CT and NMR). Clinically important neurological
signs and symptoms were present in 23 (92 %) of the cases.
Most of the patients (n = 21, 84 %) in this group had an
Table 1 Baseline demographics and characteristics
Baseline parameter All
patients
(n = 120)
Prophylaxis: cohort
A
(n = 88)
Treatment: cohort
B
(n = 7)
Treatment: cohort
C
(n = 25)
Demographics
Mean age (years) 48 47 48 50
Male [n (%)] 72 (60) 57 (65) 2 (29) 13 (52)
Female [n (%)] 48 (40) 31 (35) 5 (71) 12 (48)
Lymphoma type [n (%)]
Diffuse large B cell lymphoma 80 (67.0) 62 (70.5) 6 (85.7) 12 (48.0)
Lymphoblastic lymphoma 11 (9.0) 10 (11.4) 0 (0.0) 1 (4.0)
Primary mediastinal B cell lymphoma 8 (7.0) 6 (6.8) 1 (14.3) 1 (4.0)
Primary CNS lymphoma 8 (7.0) 0 (0.0) 0 (0.0) 8 (32.0)
Peripheral T cell lymphoma 5 (4.0) 5 (5.7) 0 (0.0) 0 (0.0)
Burkitt’s lymphoma 4 (3.0) 3 (3.4) 0 (0.0) 1 (4.0)
Mantle cell lymphoma 4 (3.0) 2 (2.3) 0 (0.0) 2 (8.0)
Systemic ? measurable CNS disease [n (%)] 14 (11.7) 0 (0.0) 0 (0.0) 14 (56.0)
Isolated measurable CNS disease, n (%) 11 (9.2) 0 (0.0) 0 (0.0) 11 (44.0)
High risk (2–3 risk factorsa) [n (%)] 84 (70) 68 (77.3) 7 (100) 9 (36)
Two risk factors 57 (47.5) 51 (58.0) 2 (28.6) 4 (16.0)
Three risk factors 27 (22.5) 17 (19.3) 5 (71.4) 5 (20.0)
High risk: Special extranodal localizationb 30 (25.0) 17 (19.3) 2 (28.6) 11 (44.0)
High risk: Diagnosis (lymphoblastic and Burkitt’s
lymphoma)
15 (13.0) 13 (14.80) 0 (0.0) 2 (8.0)
Pleocytosis (lymphocytes [ 15/ll) [n (%)] 25 (20.8) 0 (0.0) 7 (100 %) 21 (84 %)
CSF cerebrospinal fluid, CNS central nervous system
a Risk factors defined as International Prognostic Index score 3ne-belevated lactate dehydrogenase, and C2 extranodal sites
b Patients with involvement at special sites, including infiltration of vertebral column, orbits, sinuses, or testes were also considered at high risk
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important pleocytosis ([15 cells/ll, mean 400/ll, range
21–4000/ll). Eleven patients (44 %) had primary and 14
(56 %) secondary CNS involvement.
Each cohort received intrathecal liposomal cytarabine,
50 mg every 2–4 weeks. The mean time from diagnosis to
the first intrathecal liposomal cytarabine injection ranged
from 78.5 days in prophylaxis cohort A to 177 days in
cohort C. The mean number of intrathecal liposomal cy-
tarabine injections was 3.1, 4.0, and 4.3 in cohorts A, B, C,
respectively. Therapy administered in subsequent groups is
summarized in Table 2.
Results
Toxicity evaluation
The overall AE incidence was 79.2 %; however, the ma-
jority of AEs were mild-to-moderate in severity (grades
1–2); none of the patients developed grade 4 AEs
(Table 3). The most common AEs were headaches
(69.2 %), nausea (20.8 %), and fever (16.7 %). The inci-
dence of headaches was higher in cohort B than cohorts A
and C (85.7 vs. 64–69 %), while nausea (40 vs.
14.8–28.6 %) and neurological deficits (28 vs. 0–3.4 %)
were more frequently reported in cohort C than cohorts A
and B (Table 1). The incidences of fever (24–28.6 vs.
13.6 %) and dizziness (14.3–16 vs. 3.4 %) were higher in
cohorts B and C than in cohort A (Table 3). Myelopathy
(cauda equine syndrome) was reported in two cases (one in
cohort A, one in cohort C, 1.1 and 4 %, respectively). In
both cases, it was mild (CTCAE grade 1), described as
saddle paraesthesia involving S4–S5 dermatomes, without
incontinence and motor dysfunctions. It resolved without
any dedicated treatment after 2 and 3 days. Transitory
neurological deficits were described in 10 cases (three
patients with CTCA grade 2, 7 with grade 3): three in
cohort A and seven in cohort C. In total, four cases of
arachnoiditis (grade 2 and 3) were reported after liposomal
cytarabine, including two patients treated with systemic
high-dose cytarabine and MTX in cohort C and two
patients receiving CNS prophylaxis, while on R-CHOP in
Table 2 CNS disease type and treatment/prophylaxis details
Baseline parameter All
patients
(n = 120)
Prophylaxis:
cohort A
(n = 88)
Treatment:
cohort B
(n = 7)
Treatment:
cohort C
(n = 25)
Proportion treated for de novo disease [n (%)] 107 (89.2) 84 (95.5) 6 (85.7) 17 (68.0)
Proportion treated for relapsed disease [n (%)] 13 (10.8) 4 (4.5) 1 (14.3) 8 (32.0)
Mean time from diagnosis to first liposomal cytarabine injection (days) 136 78.5 116 177
Number of liposomal cytarabine injections [mean (range)] 3.4 (1–8) 3.1 (1–7) 4.0 (1–7) 4.3 (2–8)
Systemic low-dose chemotherapy [n (%)] 94 (78.3) 76 (86.3) 7 (100.0) 11 (44.0)
R-CHOP 91 (75.8) 73 (83.0) 6 (85.7) 9 (36.0)
R-CVP 4 (3.3) 2 (2.3) 0 (0.0) 2 (8.0)
Other chemotherapy 3 (2.5) 1 (1.1) 1 (14.3) 0 (0.0)
Systemic, CNS-penetrating chemotherapy [n (%)] 25 (20.8) 12 (13.6) 0 (0.0) 13 (52.0)
R-CODOXM/R-IVAC (in BL) 3 (2.5) 2 (2.3) 0 (0.0) 1 (4.0)
EVAP (in LBL) 8 (6.7) 8 (9.1) 0 (0.0) 0 (0.0)
R-CHOP/RHAD (in MCL) 2 (1.7) 2 (2.3) 0 (0.0) 0 (0.0)
MA/IVAC 7 (5.8) 0 (0.0) 0 (0.0) 7 (28.0)
ESHAP 2 (1.7) 0 (0.0) 0 (0.0) 2 (8.0)
RHAD 1 (0.8) 0 (0.0) 0 (0.0) 1 (4.0)
R-CHOP/MTX 1 (0.8) 0 (0.0) 0 (0.0) 1 (4.0)
IVAC 1 (0.8) 0 (0.0) 0 (0.0) 1 (4.0)
Whole brain radiation therapy [n (%)] 18 (15.0) 0 (0.0) 0 (0.0) 18 (72.0)
Autologous stem cell transplant post-chemotherapy (consolidation or
relapse)
19 (15.8) 16 (18.2) 0 (0.0) 3 (12.0)
BL Burkitt’s lymphoma, CNS central nervous system, CT chemotherapy, ESHAP etoposide combined with solumedrol, high-dose cytarabine and
platinum-based chemotherapy, EVAP etoposide combined with vinblastine, adriamycin and prednisolone in patients with LBL, IVAC ifosfamide,
etoposide and high-dose cytarabine, LBL lymphoblastic lymphoma, MA/IVAC methotrexate and cytarabine administered in alternate cycles with
IVAC, MCL mantle cell lymphoma, R-CHOP rituximab combined with cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin) and
prednisone, R-CODOXM/R-IVAC rituximab plus cyclophosphamide, vincristine, doxorubicin, and high-dose methotrexate followed by rituximab
in combination with IVAC in patients with BL, R-CVP rituximab plus cyclophosphamide, vincristine and prednisone, R-CHOP/RHAD R-CHOP
followed by rituximab plus high-dose cytarabine according to the Nordic protocol in patients with MCL
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cohort A. Arachnoiditis was diagnosed in patients where
important (grades 2–3) headaches were accompanied by
fever, neck stiffness, nausea, and vomiting. One arach-
noiditis was described after the first, two after the third, and
one after the fourth Depocyte dose.
Only seven (5.8 %) patients developed grade 3 AEs: five
(4.1 %) headaches, one (0.8 %) fever, one (0.8 %) nausea:
six of them were reported in cohort A (CNS prophylaxis)
and one in cohort C (CNS lymphoma therapy). There were
no grade 3 AEs in cohort B, compared with 4.0 % in cohort
C and 6.8 % in cohort A.
The frequency of mild-to-moderate (CTCAE grades
1–2) AEs did not increase with the number of Depocyte
intrathecal injections; however, grade 3 events usually
happened later, after the second (mean fourth) adminis-
tration. The incidence of AEs was not correlated with the
frequency of lumbar punctures: 81 versus 67 % (P–NS) for
patients exposed to Depocyte every 2 and 4 weeks, re-
spectively. AEs were seldom the cause of premature
treatment/prophylaxis termination.
Cytological response
None of the 88 patients to whom intrathecal cytarabine
were given as prophylaxis, developed pleocytosis, nor did
they incur CNS relapse at the average follow-up of 3 years.
Although the CSF assessment was made using the cyto-
logical method, which is less specific than flow cytometry,
the length of response provides the additional confirmation
of Depocyte efficacy. Twelve patients (13.6 %) received
induction concomitant systemic chemotherapy in doses
penetrating to the CNS, and a further 16 (18.2 %) were
treated with high-dose chemotherapy supported by au-
tologous stem cell transplants for systemic relapse.
In cohort B (mean pleocytosis 39 cells/ll, range 15–164/
ll), the cytological response was excellent, and our ob-
servations confirmed the efficacy of Depocyte. In 3/7 cases,
a complete response was observed after the first, in 2/7 case
after the second and in 2/7 cases after the third intrathecal
administration. As responses were not assessed by flow
cytometry, it was recommended to carry on with therapy
and to administer four doses (range 2–6).
In cohort C, CSF involvement was documented in 21/25
(84 %) cases (mean pleocytosis 400/ll, range 21–4000/ll).
Complete cytological remission was obtained in 16 cases
(at the end of therapy 20/25 patients had a cytological CR).
A summary of the cytological response rates is shown in
Table 4.
Response assessment
In total, 98 of 120 (82 %) patients were still alive after an
average follow-up of 3 years, including 77 (87.5 %) in
cohort A, all 7 (100 %) patients in cohort B and 14 (56 %)
in cohort C:
• Cohort A: at three-year follow-up, PFS and OS were 80
and 88 %, respectively. More detailed efficacy analysis
of CNS relapse prophylaxis in this group has been
addressed previously, in a different paper [24].
• Cohort B: median OS and EFS had not been reached at
three-years follow-up (all patients achieved CR, all
were alive, none had progressed). With seven patients
Table 3 Summary of adverse events reported in cohorts A–C
Adverse events All patients
(n = 120)
Prophylaxis: cohort A
(n = 88)
Treatment: cohort B
(n = 7)
Treatment: cohort C
(n = 25)
Individual adverse events (CTCAE any grade)
Adverse events (any grade) [n (%)] 95 (79.2) 69 (78.4) 6 (85.7) 20 (80.0)
Headache [n (%)] 83 (69.2) 61 (69.3) 6 (85.7) 16 (64.0)
Nausea [n (%)] 25 (20.8) 13 (14.8) 2 (28.6) 10 (40.0)
Fever [n (%)] 20 (16.7) 12 (13.6) 2 (28.6) 6 (24.0)
Neurological deficits [n (%)] 10 (8.3) 3 (3.4) 0 (0.0) 7 (28.0)
Dizziness [n (%)] 8 (6.7) 3 (3.4) 1 (14.3) 4 (16.0)
Vomiting [n (%)] 8 (6.7) 5 (5.7) 1 (14.3) 2 (8.0)
Myelopathy [n (%)] 2 (1.7) 1 (1.1) 0 (0.0) 1 (4.0)
Individual adverse events (CTCAE grade 3)
Grade 3 events [n (%)] 7 (5.8) 6 (6.8) 0 (0.0) 1 (4.0)
Headaches [n (%)] 5 (4.1) 4 (4.5) 0 (0.0) 1 (4.0)
Fever 1 (0.8) 1 (1.1) 0 (0.0) 0 (0.0)
Nausea 1 (0.8) 1 (1.1) 0 (0.0) 0 (0.0)
Only seven patients developed grade 3 AEs: five headaches, one fever, one nausea: six of them were reported in cohort A (CNS prophylaxis), one
in cohort C (CNS lymphoma therapy)
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included in this cohort, no conclusions can be drawn;
however, our observation confirmed the exceptional
efficacy of liposomal cytarabine in this clinical setting
(registration indication).
• Cohort C: Clinical responses were observed in 19 of 25
(76 %) patients, including 10 (40 %) complete re-
sponses (CR) and 9 (36 %) partial responses (PR).
Neurological response rates (72.7 and 78.6 %) were
similar in lymphoma patients with primary and sec-
ondary CNS involvement. The response rate was 75 %
in patients with DLBCL (41.7 % CR) and PCNSL
(50 % CR); other histological subtypes were too rare to
assess them separately (Table 5). The response rate was
66.6 % (16.6 % CR and 50.0 % PR) with CNS-directed
therapy with liposomal cytarabine ? WBRT (±low-
dose chemotherapy). A similarly high neurological
response rate was achieved with liposomal cytarabine
plus high-dose CNS-penetrating chemotherapy with
(85.7 %, including 57.1 % CR) or without (83.3 %,
including 66.6 % CR) WBRT. Median EFS was
10 months (Fig. 1), and median OS was 4.8 years.
Discussion
Liposomal cytarabine has favourable pharmacokinetics and
possibly better biodistribution in comparison with in-
trathecal MTX and cytarabine. Due to liposomal formula-
tion, its half-life in CSF is more than 30 times longer
(141 h compared to 3.4 h and 4.5 h for MTX and cytara-
bine, respectively). In this paper, we have addressed the
feasibility and toxicity issues. The retrospective nature of
our study was not designed to make definite clinical
recommendations.
Table 4 Summary of cytological response rates.a
Cytological (CSF) response Treatment: cohort A
(CSF pleocytosis, n = 7)
Treatment: cohort B
(Measurable CNS involvement, n = 25)
Response (CSF count \ 15 lymphoma cells/ml) [n (%)] 7 (100) 21 (84)
Failure (CSF count C 15 lymphoma cells/ml) [n (%)] 0 (0) 5 (16)
CNS central nervous system, CSF cerebrospinal fluid
a CSF cell count normalization (response \ 15 cells/ll) or clinically important pleocytosis (failure C 15 cells/ll) in cohorts A and B
Table 5 Summary of clinical responses by lymphoma type or concomitant therapy
Cohort B: overall responses ORR
n (%)
CR
n (%)
PR
n (%)
SD
n (%)
PD
n (%)
All patients (n = 25) 19 (76.0) 10 (40.0) 9 (36.0) 2 (8.0) 4 (16.0)
Responses by individual lymphoma type
Diffuse B cell lymphoma (n = 12) 9 (75.0) 5 (41.7) 4 (33.3) 1 (8.3) 2 (16.7)
Primary CNS lymphoma (n = 8) 6 (75.0) 4 (50.0) 2 (25.0) 1 (12.5) 1 (12.5)
Mantle cell lymphoma (n = 2) 2 (100.0) 0 (0.0) 2 (100.0) 0 (0.0) 0 (0.0)
Burkitt’s lymphoma (n = 1) 1 (100.0) 1 (100.00) 0 (0.0) 0 (0.0) 0 (0.0)
Lymphoblastic lymphoma (n = 1) 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0)
Primary mediastinal B cell lymphoma (n = 1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
Responses by regimen added concomitantly with liposomal cytarabine
WBRT (±low-dose systemic chemotherapy) (n = 12) 8 (66.6) 2 (16.6) 6 (50.0) 2 (16.6) 2 (16.6)
High-dose CNS-penetrating chemotherapy (n = 6) 5 (83.3) 4 (66.6) 1 (16.7) 0 (0.0) 1 (16.7)
WBRT ? high-dose CNS-penetrating chemotherapy (n = 7) 6 (85.7) 4 (57.1) 2 (28.6) 0 (0.0) 1 (14.3)
CNS central nervous system, CR complete response, ORR objective response rate, PR partial response, PD progressive disease, SD stable disease,
WBRT whole brain radiation therapy
Fig. 1 Event-free survival in patients in cohort C* (n = 25)
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The relatively short time interval from initial diagnosis
of NHL to CNS involvement suggests that seeding of the
CSF with malignant lymphoma cells occurs early in the
natural course of the disease [25, 26]. Therefore, prophy-
laxis or ‘early treatment’ could help prevent/reduce lep-
tomeningeal and/or parenchymal CNS involvement in
patients with systemic disease. The necessity of prophy-
laxis—indisputable in lymphoblastic and Burkitt lym-
phomas—depends on proper identification of the high risk
group in other lymphoma subtypes. There seems to be no
difference of the incidence of CNS involvement between
DLBCL, primary mediastinal B cell lymphoma or periph-
eral T cell lymphomas (including anaplastic T large cell,
angioimmunoblastic T cell lymphoma, and others) [27]. In
our study, those subjected to CNS prophylaxis only in-
cluded patients with well-established risk factors: ‘‘specific
localizations’’ or at least two of the following three fea-
tures: IPI 3–5, elevated LDH, 2 or more of extranodal lo-
calizations [28]. As ‘‘specific localizations’’, we regarded
only lymphoma infiltration of the testis, breast, epidural
space, or cranial air sinuses [29–32]. Such an approach was
consistent with guidelines published recently in BJH, with
a level of evidence of 1b: one could have expected 7–15 %
incidence of CNS relapse in those patients [33].
A recent retrospective database analysis evaluated CNS
relapse rates in 435 high-risk aggressive lymphoma pa-
tients who mostly ([95 %) received systemic chemother-
apy without prophylaxis [16]. Over two-thirds of CNS
relapses occurred within the first year of diagnosis, the
overall CNS relapse rate was 7.1 %, and the median time to
CNS relapse was 8.1 months with CHOP and 6.7 months
with R-CHOP treatment. The projected three-year CNS
relapse rates were 6.4 % with R-CHOP and 9.7 % for
CHOP, respectively [16].
Our data which show no relapses after 3 years confirm the
efficacy of intrathecal liposomal cytarabine prophylaxis, but
due to the retrospective nature of this study, cannot be used to
make definite clinical recommendations. However, it should
be noted that currently, we do not have a widely accepted
standard, and the level of evidence of the most commonly
used 3–6 cycles of intrathecal MTX is only 2c.
The major strength of this paper is the toxicity analy-
sis—with 120 patients, including 88 with intrathecal lipo-
somal cytarabine used in prophylactic setting, it is one of
the largest series published so far. In Polish Lymphoma
Research Group retrospective analysis liposomal cytara-
bine was well-tolerated; although 79.2 % of patients had at
least one AE, the vast majority were grades 1–2 in severity.
The most common AEs were headaches (69.2 %), nausea
(20.8 %), and fever (16.7 %), and the incidence of transi-
tory neurological deficits (8.3 %), dizziness (6.7 %) and
myelosuppression (1.7 %) was low. There were four cases
of arachnoiditis, which has been raised as a concern with
liposomal cytarabine; however, none were grade 4 or
higher in severity (n = 2 grade 3; n = 2 grade 2). They all
occurred after the third dose of the drug. Arachnoiditis can
be prevented by oral or intravenous steroids or by reducing
the dose of liposomal cytarabine to 25 mg and, perhaps, by
reducing the number of doses applied. The incidence of
cauda equine syndrome was low in our series: one case in
cohort A (1.1 %) and one in cohort C (4 %). They were
both mild and transitory, but there are AEs described in the
literature as potentially irreversible. It has been shown in a
retrospective case series that 23.3 % of patients experi-
enced Common Toxicity Criteria C Grade 3 neurotoxicity
related to the Depocyte injections. 43 % of these AEs were
permanent and may have impacted patients’ quality of life
[34]. In another small retrospective analysis, four of four-
teen patients (28 %) with high-grade NHL that received
prophylactic therapy with IT liposomal cytarabine devel-
oped moderate or severe neurotoxicity (grades 2 and 3 of
the National Cancer Institute Common Toxicity Criteria),
manifested as conus medullaris/cauda pseudotumour cere-
bri-like syndrome, after a median of 3.5 intrathecal courses
of liposomal cytarabine [35]. One case of fulminant che-
mical ventriculomeningitis following intrathecal liposomal
cytarabine administration has been described in the lit-
erature [36]. The aforementioned AEs are rare, but to avoid
them, the careful choice of which patients to subject to
liposomal cytarabine for CNS prophylaxis is necessary.
It is important to mention that all adverse events
(CTCAE 1–3) were evenly distributed in each of the co-
horts (78.4, 85.7, and 80 % in cohorts A, B, and C sub-
sequently). It is also true for important, grade 3 events,
which occurred in 6.8 % (6/88) patients prophylaxed with
Depocyte. Although they all resolved with time and
symptomatic treatment, they may be potentially dangerous,
causing long-lasting neurological consequences. It is a
debatable whether such a possibility, which is fully ac-
ceptable for patients treated for CNS involvement (cohorts
B and C), is allowed for prophylactic settings.
No CTCAE grade 4 AEs and the relatively low inci-
dence of grade 3 adverse reactions in our series could have
been due to: mandatory hospitalization allowing for proper
hydration prior to lumbar puncture, recommended
horizontal position for 6–8 h after procedure (also impor-
tant for improving intraventricular drug perfusion) [37] and
concomitant chemotherapy regimens with systemic ster-
oids. To improve lumbar puncture feasibility atraumatic,
noncutting spinal needles (22 gauge or lower) should be
used. They decrease the risk of CSF leaks and postlumbar
puncture headaches [38] and may also prevent cerebral
bleeding or thrombosis [39]. The early removal of the
stylet (after passage through the epidermal and subcuta-
neous tissues) may significantly improve the success rate of
lumbar punctures [40].
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An important question which needs to be addressed is
the optimal intrathecal dosing schedule. It should be
mentioned, that the optimal Depocyte dosing schedule is
not yet established: neither the optimal dose (50 mg may
not be necessary), nor its frequency (every 4 weeks seems
in our data as effective as administered with 2-week in-
tervals) or eventually the number of intrathecal adminis-
trations is known. The number of Depocyte doses may
correlate with the incidence of arachnoiditis. In our study,
we aimed to administer four doses at the time of systemic
therapy. Although the regimen was well-tolerated, 13
(15 %) patients received three and 29 (33 %) received only
two doses in our study. The main reason why patients did
not complete the planned number of intrathecal injections
was the inconvenience of having to stay in hospital over-
night after the lumbar puncture as well as the physician’s
decision. Interestingly, high cytological and neurological
response rates were still achieved despite the fact that many
patients received a lower than planned number of liposo-
mal cytarabine injections.
The cytological response was restrictive. Although it
was assessed using the cytological method which was re-
peated at each intrathecal administration, and not by more
specific flow cytometry, the length of CNS progression-
free survival in cohorts A and B is an additional argument
for Depocyte efficacy. None of those patients progressed.
In Cohort C, the cytological response rate of 84 % is above
expectation.
NHL patients with CNS involvement (cohort C) who
typically have a very poor prognosis also appeared to
benefit from additional intrathecal liposomal cytarabine,
with a 76 % neurological response rate, 40 % CR rate, and
a striking 4.8-year median OS. Notably, although sample
numbers were small, the highest neurological overall re-
sponse rate (ORR) and CR rates were achieved in patients
who received intrathecal liposomal cytarabine and high-
dose CNS-penetrating chemotherapy. No additional benefit
was apparent when WBRT was added to this regimen. The
toxicity of regimens containing liposomal cytarabine is
acceptable; thus, the intrathecal liposomal cytarabine plus
high-dose chemotherapy regimen may avoid the toxicities
of WBRT without compromising efficacy.
Conclusions
Our analysis has demonstrated the three-yearyear efficacy
of liposomal cytarabine regimens in the prophylaxis or
treatment of CNS involvement in high-risk patients with
aggressive NHL. The toxicity profile was acceptable, even
in a prophylaxis setting; thus, allowing the recommenda-
tion of liposomal cytarabine in chosen, high-risk patients.
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